Tarot Capital发布治理激励grant digest，讨论Standard BioTools和UL Solutions的旧激励安排

Solid collection of interesting grants and governance signals in this one.

As always, the grant structures tell you what the boards are underwriting. Whether the businesses deliver is the part you have to handicap yourself.

Some quick mentions of others doing great work in the space:

Thanks to at YAVB for the shoutout in his latest post, where he discusses a [very interesting grant ](https://www.yetanothervalueblog.com/p/corporate-dark-arts-the-strangest)at (which will be discussed in a future digest!).

The aptly named does very good research work with a governance-aware perspective. [Check out](https://showmetheincentives.substack.com/p/fulcrum-therapeutics-inc-fulc) their discussion on .

###### **Disclaimer: This newsletter is not investment advice. The information provided is for informational purposes only and should not be considered investment advice. You should consult with a financial advisor or other professional to determine your investment goals and risk tolerance. Any investment decisions you make are solely your responsibility. The author may hold a position in discussed securities at the time of publication and may transact in the security without further notice.**

Tarot Capital is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
**

### Case Study: Standard BioTools (LAB)


This is an interesting case study for your reference on how solid governance signals don’t mean that the equity is going to do well.

**Historic Business Overview:** Standard BioTools (fka Fluidigm) was a life-sciences tools company built on mass cytometry and microfluidics. In January 2026 it sold SomaLogic to Illumina for $350M upfront and up to $425M total, leaving roughly $550M of cash and about $1B of U.S. NOL carryforwards against a continuing-operations business doing only ~$85M of revenue. Management had been explicit that the plan is to deploy the cash and NOLs into “disciplined M&A.”

Put differently: the market valued the operating business at roughly nothing — this is, functionally, a cash-rich shell with a stated roll-up mandate and a Danaher-style operating playbook.

**Grant Overview:** The [May 21, 2026 filing](https://www.sec.gov/Archives/edgar/data/1162194/000119312526245181/lab-20260521.htm) adopts a new 2026 Change of Control and Severance Plan (term to August 4, 2028) covering CFO Alex Kim and CBO Sean Mackay; the CEO remains under a separate 2023 plan. Upon departure, they receive 12 months of base salary, a pro-rated bonus, and COBRA on a qualifying termination, scaling to a 150% lump sum inside the CiC window. Note the near-term equity carve-out:
**

**If the termination occurs on or prior to August 27, 2026, 100% vesting acceleration of the executive’s then-outstanding and unvested equity awards**, provided that, if an equity award is to vest… based on the achievement of performance criteria, then… 100% of such equity award will vest assuming the applicable performance criteria had been achieved at target levels.

Eight days later, on [May 29, 2026](https://www.sec.gov/Archives/edgar/data/1162194/000119312526255403/lab-20260529.htm), the Human Capital Committee granted CBO Sean Mackay 500k RSUs under the 2026 Equity Incentive Plan, effective June 20, 2026:
**

Subject to Mr. Mackay continuing to provide services to the Company through the applicable vesting dates, **40% of the RSU Award will vest on June 20, 2027, and the remaining 60% of the RSU Award will vest on June 20, 2028**. The RSU Award is also subject to the provisions of the **Company’s 2026 Change of Control and Severance Plan** under which Mr. Mackay participates, and his Participation Agreement thereunder.

Sequencing is important here: the board refreshed the change-of-control terms, then granted fresh equity into it for the Chief Business Officer (deal-execution). Because the grant is effective June 20, it spends its two months inside that August 27 window, meaning it would 100% accelerate on essentially any termination through late August before reverting to standard change-of-control-only acceleration.

**What Happened:** On June 6th, the business signs an all-stock reverse merger with Treeline Biosciences. Treeline has a $2.5B valuation against LAB’s ~$500M, so legacy shareholders would end up with ~16% of the combined business (future TRLN). The remaining tools franchise is going to get divested into a CVR. Shares were down fairly dramatically on the announcement.

So this is pretty clean from the board/management alignment perspective. The governance signal in this case does its job (cleaning up for CiC) all the while management is publicly signaling that they’re looking to allocate the capital. Now, personally, I probably wouldn’t have basically traded that cash for a lotto ticket—I mean biotech, really?—but in the likely outcome that the team gets kicked after merger, they get a nice little gift-wrapped goodbye.

Remaining shareholders basically get a sliver of an oncology pipeline + a CVR (which I think have a pretty awful record of working out). Management doesn’t care though!

### UL Solutions (ULS)


**Business Overview:** UL Solutions is the for-profit testing, inspection and certification (TIC) arm of the 130-year-old Underwriters Laboratories, which is behind the “UL” safety mark on the back of half the electronics in your house. It IPOd in April 2024 and operates three segments (Industrial, Consumer, Software & Advisory), with the nonprofit parent still in control via Class B shares. FY2025 revenue was $3.05B with a solid ~26% adj. EBITDA margin; Q1 2026 kept the run going at MSD growth.

The stock has been one of the better post-IPO compounders around and reminiscent of a pre-COVID compounders. In other words, it’s a quality business at a premium multiple (~50x adjusted earnings, sheesh).

**Grant Overview:** On [June 1, 2026](https://www.sec.gov/Archives/edgar/data/1901440/000190144026000019/uls-20260601.htm), the board granted CEO Jennifer Scanlon a special, one-time, 100% price-hurdle PSU grant. Notably, the board granted this instead of raising her annual long-term incentive. They explicitly extended the horizon to five years and kept the incremental pay fully at-risk.

Service vests 30%/30%/40% on the third, fourth, and fifth anniversaries and the payout runs off two alternative metrics, both measured against a ~$90 baseline:
**

If the Company’s stock price increases to at least **$135.81** at any time from December 1, 2028 through June 1, 2031… 50% to 100% of the PSUs are eligible to be earned… A 100% payout will be earned if the Company’s stock price increases to at least **$181.08**… Stock price appreciation is measured by comparing the highest 60-trading day average closing price during the Stock Price Metric Performance Period to $90.54…

Alternatively, if the Company’s TSR is at or above the 55th percentile of the TSR of S&P 500 index companies… 60% of the PSUs are eligible to be earned… inclusive of PSUs earned under the stock price metric.

Basically, the board is asking for the stock to grow +50% to +100% over five years and is making all of the CEO’s incremental comp contingent on getting there.

**Potential Thesis:** Two things to note here:

1) the hurdles are anchored to a 60-day pre-grant average ($90.54) that sits ~9% *below* the grant-date close, so in spot terms the bogeys are closer to **+36%/+81%** than the headline +50%/+100%, which works out in the CEO’s favor.

2) the relative-TSR path doesn’t get her too far, as beating ~55% of the S&P 500 caps out at 60% of the award. The full payout still demands the stock 2x off the base.

Put differently, the board built in a slight cushion against a flat tape but is still aiming for absolute price appreciation. The straightforward counterargument is valuation: doubling from ~50x adjusted earnings either requires the multiple to hold while MSD organic growth, steady margin expansion, and tuck-in M&A compound for half a decade (without facing any issues at all), or it requires more multiple on an already-rich name.

Worth noting too that insiders, have been routine net sellers over the past year, but we find that selling isn’t a particularly strong signal in isolation. Just something to monitor. In conclusion, this is a credible, multi-year alignment grant that says the board thinks the compounding has years left to run, offset by the high sticker price.

[Share](https://tarotcapital.substack.com/p/2026-grants-digest-vol-9?utm_source=substack&utm_medium=email&utm_content=share&action=share)

### Rapid7 (RPD)
LAB, ULS, RPD, ABAT, SGMT